Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.
Kathryn M MillerClaire F FriedmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
SHR-1701, a bispecific fusion protein directed against PD-L1 and TFG-β, demonstrates promising clinical activity in advanced/recurrent cervical cancer; a recent study serves as a proof of principle that the TGF-β pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so.